메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
심나연 (이화여자대학교) Cho Hanhee (College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Woman’s University) Jeon Seong Ik (College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Woman’s University) 김광명 (이화여자대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation Vol.54 No.1
발행연도
2024.1
수록면
13 - 36 (24page)
DOI
10.1007/s40005-023-00646-7

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background In recent studies of cancer therapies, chemodrugs have attracted interest, acting not only as traditional chemotherapeutic agents but also as anticancer immune-activating agents. Specific types of chemodrugs have been demonstrated to exhibit superior anticancer efficacy to others through directly exerting toxic effects on cancer cells and indirectly by inducing immunogenic cell death (ICD) to recruit immune cells to kill them. However, chemodrug-based ICD has not yet achieved satisfactory therapeutic outcomes because of various limitations, including the poor tumor delivery efficiency of chemodrugs, the strong resistance of tumor tissues to chemodrugs, and the immunosuppressive tumor microenvironment. Area covered This review briefly introduces ICD-inducing chemodrugs and their properties, and then explains the advantages of nanomedicine in ICD-inducing chemodrug delivery. Further, studies on chemodrug-loaded nanomedicine-based combined immunotherapy are discussed, with a focus on the cooperative effect of ICD induction with other co-administered immunotherapeutic modalities. Expert opinion It is possible to obtain better pharmacokinetic properties and tumor accumulation efficiency when using chemodrug-loaded nanomedicines compared with free chemodrugs, resulting in stronger ICD-inducing effects. The tumortargeting efficiency of nanomedicines can be further improved by their modification with active targeting or tumor stimuliresponsive moieties while diminishing their undesirable biodistribution. Nanomedicines also facilitate the simultaneous delivery of ICD-inducing chemodrugs and other immunotherapeutic agents; these act synergistically to enhance the efficacy of ICD-based combined immunotherapy, even against highly drug-resistant and immunosuppressive tumors. Nanomedicine is expected to provide a promising approach to overcoming the challenges of ICD-inducing chemodrug-based combination cancer immunotherapy.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0